United Fufangkushen paclitaxel liposome injection in the treatment of malignant ascites efficacy and safety analysis
TANG Ling;PU Ying;JI Fa-he;TAN Lin-shen;Department of Oncology,The Generol Hospital of Shenyang Military Command;
Objective To explore paclitaxel liposome combined Fufangkushen injection in treatment of malignant ascites efficacy and safety. Methods Totally 80 cases of patients with malignant ascites,using random number table all the patients were divided into five groups,16 cases in each group,into the A group were injected with liposomal paclitaxel 30 mg,Fufangkushen injection liquid 30ml; intraperitoneal injection into the group B liposomal paclitaxel 60 mg,compound Fufangkushen Injection 30 ml; group C injected into the liposomal paclitaxel 30 mg; D group was injected into the liposomal paclitaxel 60mg; the E group were former weekly injection of ascites volume ultrasound probe to monitor changes in the amount of ascites and symptoms of change; injection of cisplatin 40 mg. Results( 1) Group B clinical total effective rate was significantly higher than A and E group( P 0. 05);( 2) Clinical total effective D group was obviously higher than that of group C( P 0. 05);( 3) A group of nausea and vomiting,fever incidence was significantly lower in group C,and thrombocytopenia were significantly lower than group B( P 0. 05);( 4) Group B was lower than that in group E incidence of nausea and vomiting,fever incidence was lower than that in group D( P 0. 05);( 5) Abdominal distension,group B patients symptoms such as shortness of breath,difficulty breathing is most significantly. Conclusion Paclitaxel liposome unite Fufangkushen injection can effectively inhibit the generation of ascites,reduce chemotherapy toxicity,improve quality of life of patients. The method is simple,the effect is significant,and high security,is worthy of wider promotion.
【CateGory Index】： R730.5